Dibenzyl ether → 4-[(S)-2-({5-[2-((S)-2-Cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1H-pyrazole-3-carbonyl}-amino)-6-hydroxy-hexanoyl]-piperazine-1-carboxylic acid butyl ester
Reaction equation
[CH2:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][N:11]([C:14](=[O:58])[C@@H:15]([NH:28][C:29]([C:31]2[CH:35]=[C:34]([O:36][CH2:37][C:38]([N:40]3[CH2:44][CH2:43][CH2:42][C@H:41]3[C:45](=[O:51])[NH:46][CH:47]3[CH2:50][CH2:49][CH2:48]3)=[O:39])[N:33]([C:52]3[CH:57]=[CH:56][CH:55]=[CH:54][CH:53]=3)[N:32]=2)=[O:30])[CH2:16][CH2:17][CH2:18][CH2:19][O:20]CC2C=CC=CC=2)[CH2:10][CH2:9]1)=[O:7])[CH2:2][CH2:3][CH3:4].C(OCC1C=CC=CC=1)C1C=CC=CC=1>C(OCC)(=O)C>[CH2:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][N:11]([C:14](=[O:58])[C@@H:15]([NH:28][C:29]([C:31]2[CH:35]=[C:34]([O:36][CH2:37][C:38]([N:40]3[CH2:44][CH2:43][CH2:42][C@H:41]3[C:45](=[O:51])[NH:46][CH:47]3[CH2:48][CH2:49][CH2:50]3)=[O:39])[N:33]([C:52]3[CH:53]=[CH:54][CH:55]=[CH:56][CH:57]=3)[N:32]=2)=[O:30])[CH2:16][CH2:17][CH2:18][CH2:19][OH:20])[CH2:10][CH2:9]1)=[O:7])[CH2:2][CH2:3][CH3:4]Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
To a solution of 819 mg 4-[(S)-6-Benzyloxy-2-({5-[2-((S)-2-cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1H-pyrazole-3-carbonyl}-amino)-hexanoyl]-piperazine-1-carboxylic acid butyl ester in 20 ml ethyl acetate were added under argon 100 mg Pd/C (10%) and the suspension was stirred under an atmosphere of hydrogen (3 bar) for 12 h. The suspension was filtered over a plug of Celite® and washed with ethyl acetate. The crude product obtained after evaporation of the solvent was purified by preparative HPLC (C18 reverse phase column, elution with a water/MeCN gradient with 0.1% TFA) to give a mixture of the title compound (8 mg) and unreacted benzyl ether which was subjected to the same hydrogenolysis conditions described above to give the title compound.
Workup
- filtrationThe suspension was filtered over a plug of Celite®
- washwashed with ethyl acetate
- customThe crude product obtained
- customafter evaporation of the solvent
- customwas purified by preparative HPLC (
- washC18 reverse phase column, elution with a water/MeCN gradient with 0.1% TFA)
- customto give
Sources & evidence
- ORD record
- ord-2f9955f1299c417fa4b0f179a40cd6f3
- Source dataset
- uspto-grants-2013_04
- Patent number
- US08426420B2
Reaction notes
Loading…